DGX

Quest Diagnostics
D

DGX

Arincen63/100B

Quest Diagnostics cash on hand 1996–2026

Quest Diagnostics had 797.00M USD in cash and short-term investments on 30 September 2026, up 84.5% on a year before. At the end of fiscal year 2025 it had 420.00M USD.

Last updated 7 Nov 2026 · Next report 9 Feb 2027

Cash on hand

Growth

Fiscal yearPeriod endingCash on handGrowthTotal debtNet cash
Latest quarter30 Sept 2026797.00M+84.49%6.29B-5.49B
FY202531 Dec 2025420.00M-23.50%6.92B-6.50B
FY202431 Dec 2024549.00M-19.97%7.09B-6.54B
FY202331 Dec 2023686.00M+117.78%5.50B-4.81B
FY202231 Dec 2022315.00M-63.88%4.71B-4.40B
FY202131 Dec 2021872.00M-24.70%4.77B-3.90B
FY202031 Dec 20201.16B-2.85%4.81B-3.65B
FY201931 Dec 20191.19B+782.96%5.42B-4.22B
FY201831 Dec 2018135.00M-1.46%3.99B-3.86B
FY201731 Dec 2017137.00M-61.84%3.86B-3.72B
FY201631 Dec 2016359.00M+169.92%3.73B-3.38B
FY201531 Dec 2015133.00M-30.73%3.65B-3.52B
FY201431 Dec 2014192.00M+2.67%3.76B-3.57B
FY201331 Dec 2013187.00M-36.74%3.33B-3.15B
FY201231 Dec 2012295.60M+79.26%3.36B-3.07B
FY201131 Dec 2011164.90M-63.30%4.02B-3.86B
FY201031 Dec 2010449.30M-15.91%2.99B-2.54B
FY200931 Dec 2009534.30M+110.44%3.11B-2.57B
FY200831 Dec 2008253.90M+51.50%3.08B-2.83B
FY200731 Dec 2007167.59M+12.00%3.54B-3.37B
FY200631 Dec 2006149.64M+62.42%1.56B-1.41B
FY200531 Dec 200592.13M+25.69%1.59B-1.50B
FY200431 Dec 200473.30M-52.70%1.10B-1.03B
FY200331 Dec 2003154.96M+60.12%1.10B-947.70M
FY200231 Dec 200296.78M-20.89%822.54M-725.76M
FY200131 Dec 2001122.33M-28.66%821.74M-699.41M
FY200031 Dec 2000171.48M+528.12%1.03B-854.64M
FY199931 Dec 199927.30M-86.55%1.22B-1.19B
FY199831 Dec 1998202.90M+25.48%464.80M-261.90M
FY199731 Dec 1997161.70M+285.37%514.80M-353.10M
FY199631 Dec 199641.96M—535.79M-493.83M

Figures in USD at the end of each period. Net cash is cash and short-term investments less total debt; book value per share is on the diluted share count. The latest column is the most recent quarter.

See also:Revenue,Net income,EPS,Shares outstanding,Operating income,Total debt,Free cash flow,Stock buybacks,Balance sheet

Common questions about Quest Diagnostics's cash

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.